Fully Defined 3D Culture Substrate for Cancer Research

Hits:23   Date: 4/9/2026

Amsbio reports how researchers at the Graduate School of Medicine, Kyoto University (Japan) have cultured patient-derived colorectal cancer cells in 3D using their MatriMix 511 extracellular matrix (ECM).

In this study** the researchers demonstrated that MatriMix supported robust cancer organoid formation, and that the organoids retained biologically relevant differences between tumour stages. By comparison, alternative matrices evaluated showed limited or no metastatic marker expression. The researchers concluded that MatriMix offers the ability to create models that better reflect in vivo tumour biology and thus is highly relevant for cancer modelling and drug response studies.

Colorectal cell organoid formation using MatriMix

Dr Phillip Boder, Cell & Gene Therapy Business Manager for Amsbio commented “Colorectal cancer is one of the commonest types of cancer worldwide, with tens of thousands of deaths per year reported. Although cytotoxic and molecularly targeted drugs have improved the patient survival, it is still challenging to treat metastatic colorectal cancer. The ability of MatriMix to support organoid formation that better reflects patient tumour biology provides a valuable tool for cancer researchers. In addition to improving experimental reproducibility, MatriMix offers superior control of experimental conditions compared to undefined matrices.”
Composed of fully defined collagen type I and III, laminin-511 E8 fragments, and hyaluronic acid, MatriMix is a ready-to-use 3D culture substrate product optimized for culturing patient derived cancer cells.

For further information on MatriMix please visit https://www.amsbio.com/3d-cell-culture-extracellular-matrices/matrimix or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.

To read the University of Kyoto study** in full please visit https://aacrjournals.org/mct/article/17/10/2187/272549/A-Chemosensitivity-Study-of-Colorectal-Cancer

Amsbio, part of the Europa Biosite group, is a leading life sciences company supporting drug discovery, translational research, and cell and gene therapy across Europe, North America, and wider international markets. With in depth expertise in advanced cell culture, 3D cell models, and cryopreservation, Amsbio is well placed to help researchers progress from early discovery through to clinical and GMP-ready applications. The company’s portfolio of innovative products and services supports multiple stages of the research pipeline, spanning target discovery, assay development, and disease modelling, through to stem cell and organoid-based research. Key solutions include the integrated stem call platform combining StemFit™ media, iMatrix™ recombinant laminins, and CELLBANKER™ cryopreservation technology, alongside extracellular matrix technologies, biospecimens, glycobiology tools, kits and assays, and a wide range of custom services including viral delivery. Drawing on extensive GMP expertise and a comprehensive human and animal biorepository, Amsbio is internationally recognized for delivering high-quality, application-ready products and services. Amsbio has a consistent record of close scientific collaboration with partners in academic, biotech, and pharmaceutical markets to translate innovation from bench to bedside.

---------------------

Worldwide HQ

AMS Biotechnology Europe Ltd (Amsbio)
2-3, Munro House
Trafalgar Way
Bar Hill
Cambridge, CB23 8SQ
UK
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com
Web www.amsbio.com
 
North American HQ
 
Amsbio LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel: +1.617.945.5033
Tel: +1.800.987.0985 (toll free)
Email: info@amsbio.com
Web www.amsbio.com